➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Baxter
AstraZeneca
Moodys
Express Scripts

Last Updated: April 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Lucerastat

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Lucerastat?

Lucerastat is an investigational drug.

There have been 6 clinical trials for Lucerastat. The most recent clinical trial was a Phase 1 trial, which was initiated on December 15th 2018.

The most common disease conditions in clinical trials are Fabry Disease and [disabled in preview]. The leading clinical trial sponsors are Idorsia Pharmaceuticals Ltd., Actelion, and [disabled in preview].

There are fifty-eight US patents protecting this investigational drug and three hundred and sixty-one international patents.

Recent Clinical Trials for Lucerastat
TitleSponsorPhase
A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart FunctionIdorsia Pharmaceuticals Ltd.Phase 1
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseaseIdorsia Pharmaceuticals Ltd.Phase 3
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseaseIdorsia Pharmaceuticals Ltd.Phase 3

See all Lucerastat clinical trials

Clinical Trial Summary for Lucerastat

Top disease conditions for Lucerastat
Top clinical trial sponsors for Lucerastat

See all Lucerastat clinical trials

US Patents for Lucerastat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Lucerastat   Start Trial Cell lines for virus production and methods of use University of Georgia Research Foundation, Inc. (Athens, GA) The United States of America, as represented by the Secretary, Dept. of Health and Human Services (Washington, DC) Thermo Fisher Scientific, Inc. (Waltham, MA)   Start Trial
Lucerastat   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
Lucerastat   Start Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Start Trial
Lucerastat   Start Trial Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Lucerastat

Drugname Country Document Number Estimated Expiration Related US Patent
Lucerastat Australia AU2014215025 2033-02-05   Start Trial
Lucerastat Canada CA2899928 2033-02-05   Start Trial
Lucerastat China CN105121645 2033-02-05   Start Trial
Lucerastat China CN108588027 2033-02-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Baxter
AstraZeneca
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.